Published :
Tables : 52
Figures : 47
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3339
Recombinant Vaccines Market is predicted to value over CAGR of over 11.3% during the forecast period 2022 to 2028. Recombinant vaccines are developed using genetic engineering or recombinant DNA technology for preventing chronic diseases. These vaccines activate the T-cell and antigen trigger, thereby generating an immune response that is cell mediated against an immunogen. Rise in the number of regulatory approvals, increased advancements in device technologies, growing incidences of infectious diseases are some of the factors contributing to the recombinant vaccines market growth. Moreover, rising awareness amongst general population regarding the prevalence of chronic infectious diseases, favourable policies for reimbursements, rising disposable income are some other markets propelling the market augmentation. However, risks related to live vaccines that are attenuated, high vaccine costs, strict regulations shall possibly restrain the market growth. Many companies have received regulatory clearances in recent years has positively impacted the market growth. Merck, in December 2019, were awarded an approval from the US FDA for an Ebola vaccine named ERVEBO while in October 2017, GlaxoSmithKline received an FDA approval for their herpes zoster vaccine SHINGRIX. Such regulatory approvals for crucial drugs shall boost the proliferation of the market. These approvals are important as many people are losing their lives to these fatal diseases. According to the WHO report,2017, over 2 million deaths can be prevented every year which has paved way for newer vaccines. Market Segmentation: By Type • Subunit • Live Attenuated By Route of Administration • Parenteral • Oral By Disease Indication • Human Papillomavirus • Hepatitis B • Rotavirus • Herpes Zoster • Meningococcal B • Others By Distribution Channel • Hospitals & Retail Pharmacies • Government Suppliers • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is fragmented into type, route of administration, disease indication, distribution channel and region. The type segment is categorised into subunit and live attenuated while the route of administration segment is bifurcated into parenteral and oral. The disease indication segment is divided into human papillomavirus, hepatitis B, rotavirus, herpes zoster, meningococcal B and others. The hepatitis B segment is anticipated to hold the largest recombinant vaccines market share owing to rising prevalence of hepatitis B in developing countries where the scope of drug development is wide with key players expanding their business operations in such countries. The distribution channel segment is classified into hospital and retail pharmacies, government suppliers and others. The hospital and retail pharmacies segment is predicted to lead the market during the forecasted timeframe owing to advancements in hospital infrastructure, rise in the number of multispecialty hospitals in emerging economies and availability of skilled labour in hospital settings. Regional Analysis: The North America region is expected to subjugate the market during the forecast period owing to a rising prevalence of cancer in the region. As per the National Cancer Institute, over 16 lakh new cancer cases were recorded and over 595,000 deaths were registered in 2016. Such high incidence rate of cancer shall boost the proliferation of the market in the region. Competitive Landscape: Some of the important market players are Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi SA, Pfizer Inc., Bharat Biotech. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global recombinant vaccines market by type, by route of administration, by disease indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Recombinant vaccines are developed using genetic engineering or recombinant DNA technology for preventing chronic diseases. These vaccines activate the T-cell and antigen trigger, thereby generating an immune response that is cell mediated against an immunogen. Rise in the number of regulatory approvals, increased advancements in device technologies, growing incidences of infectious diseases are some of the factors contributing to the recombinant vaccines market growth. Moreover, rising awareness amongst general population regarding the prevalence of chronic infectious diseases, favourable policies for reimbursements, rising disposable income are some other markets propelling the market augmentation. However, risks related to live vaccines that are attenuated, high vaccine costs, strict regulations shall possibly restrain the market growth. Many companies have received regulatory clearances in recent years has positively impacted the market growth. Merck, in December 2019, were awarded an approval from the US FDA for an Ebola vaccine named ERVEBO while in October 2017, GlaxoSmithKline received an FDA approval for their herpes zoster vaccine SHINGRIX. Such regulatory approvals for crucial drugs shall boost the proliferation of the market. These approvals are important as many people are losing their lives to these fatal diseases. According to the WHO report,2017, over 2 million deaths can be prevented every year which has paved way for newer vaccines.
Market Segmentation:
By Type • Subunit • Live Attenuated By Route of Administration • Parenteral • Oral By Disease Indication • Human Papillomavirus • Hepatitis B • Rotavirus • Herpes Zoster • Meningococcal B • Others By Distribution Channel • Hospitals & Retail Pharmacies • Government Suppliers • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is fragmented into type, route of administration, disease indication, distribution channel and region. The type segment is categorised into subunit and live attenuated while the route of administration segment is bifurcated into parenteral and oral. The disease indication segment is divided into human papillomavirus, hepatitis B, rotavirus, herpes zoster, meningococcal B and others. The hepatitis B segment is anticipated to hold the largest recombinant vaccines market share owing to rising prevalence of hepatitis B in developing countries where the scope of drug development is wide with key players expanding their business operations in such countries. The distribution channel segment is classified into hospital and retail pharmacies, government suppliers and others. The hospital and retail pharmacies segment is predicted to lead the market during the forecasted timeframe owing to advancements in hospital infrastructure, rise in the number of multispecialty hospitals in emerging economies and availability of skilled labour in hospital settings.
Regional Analysis:
The North America region is expected to subjugate the market during the forecast period owing to a rising prevalence of cancer in the region. As per the National Cancer Institute, over 16 lakh new cancer cases were recorded and over 595,000 deaths were registered in 2016. Such high incidence rate of cancer shall boost the proliferation of the market in the region.
Competitive Landscape:
Some of the important market players are Merck & Co. Inc., Novartis AG, Protein Science Corporation, GlaxoSmithKline Plc., Green Cross Corporation, Bayer AG, Sanofi SA, Pfizer Inc., Bharat Biotech.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global recombinant vaccines market by type, by route of administration, by disease indication, by distribution channel and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Recombinant Vaccines Market, By Type Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 7.1 Subunit 7.2 Live Attenuated 8. Recombinant Vaccines Market, By Route of Administration Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 8.1 Parenteral 8.2 Oral 9. Recombinant Vaccines Market, By Disease Indication Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 9.1 Human Papillomavirus 9.2 Hepatitis B 9.3 Rotavirus 9.4 Herpes Zoster 9.5 Meningococcal B 9.6 Others 10. Recombinant Vaccines Market, By Distribution Channel Historical Analysis 2016 to 2020 and Forecast 2022-2028 (USD million) 10.1 Hospitals & Retail Pharmacies 10.2 Government Suppliers 10.3 Others 11. North America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Mn) Analysis By Country, 2016-2020 11.2.1. U.S. 11.2.2. Canada 11.2.3. Mexico 11.2.4. Rest of North America 11.3 Market Size (USD Mn) Forecast for North America 2022-2028 12. Latin America Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4 Market Size (US$ Mn) Forecast for Latin America 2022-2028 13. Europe Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5 Switzerland 13.2.6. Spain 13.2.7. Russia 13.2.8. Poland 13.2.9. Rest of Western Europe 13.3 Market Size (US$ Mn) Forecast for Europe 2022-2028 14. Asia Pacific Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 14.2.1 Japan 14.2.2 China 14.2.3 Singapore 14.2.4 Korea 14.2.5 India 14.2.6 Australia and New Zealand 14.2.7 ASEAN 14.2.8 Rest of Asia Pacific 14.3 Market Size (US$ Mn) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million) 15.1 Introduction 15.2 Historical Market Size (USD Mn) Analysis By Country, 2016-2020 15.2.1 GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3 Market Size (US$ Mn) Forecast for MEA 2022-2028 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 16.1 Merck & Co. Inc. 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Novartis AG 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Protein Science Corporation 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 GlaxoSmithKline Plc. 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Green Cross Corporation 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Bayer AG 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Sanofi SA 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Pfizer Inc. 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Bharat Biotech 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 17. Impact of COVID-19 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations 18. Competitive Intelligence and Competitive Matrix 18.1 Competitive Intelligence 18.2 Competitive Matrix 19. Major Deals and Strategic Alliances Analysis 19.1 Joint ventures 19.2 Mergers and acquisitions 19.3 Licensing and partnerships 19.4 Technology Collaborations 19.5 Strategic Divestments 19.6 Market Entry Strategies 20. Relevant Case Studies and Latest News Updates 21. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics